Navigation Links
Transave, Inc. Secures $12.5 Million in New Financing
Date:10/2/2008

onship, intellectual, and financial capital to yield infinite possibilities. Founded in 1908, CIT is celebrating its Centennial throughout 2008. For additional information, please go to http://www.cit.com.

About Horizon

Horizon Technology Finance Management is a privately-held independent venture debt finance company that provides senior and subordinated venture debt financing solutions to venture capital-backed technology and life science companies through its affiliated investment finance company Compass Horizon Funding Company LLC. The Horizon team has provided over $2 billion in financing to more than 750 venture capital-backed technology and life science companies over a span of 20 years. Horizon provides a compelling alternative to the restrictive structures offered by banks and corporate finance companies. Horizon's team has over 150 years of collective venture and commercial lending experience and uses its extensive knowledge, expertise, and industry relationships to provide custom venture debt products and financing solutions for its customers. Horizon has offices in Farmington, CT and the San Francisco, CA area. For more information, please visit http://www.horizontechfinance.com.

About PARI Pharma and the Investigational eFlow Nebulizer System

Arikace is delivered by the Investigational eFlow Nebulizer System. The Investigational eFlow Nebulizer System uses eFlow Technology to enable extremely efficient aerosolization of liquid medications via a vibrating perforated membrane that includes thousands of small holes that produce the aerosol mist. Compared to other nebulization technologies, eFlow Technology produces aerosols with a very high density of active drug, a precisely defined droplet size, and a high proportion of respirable droplets delivered in the shortest possible period of time. Combined with its silent mode o
'/>"/>

SOURCE Transave, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Transave, Inc. Raises $35 Million Through Series D Convertible Preferred Stock Financing
2. Northwest Secures US$1.0 Million Debt Financing
3. Trillium secures additional financing on the strength of lead program and proprietary position around the CD200 immunoregulatory pathway
4. Althea Technologies Secures $12 M Credit Line to Continue Facility Growth and Expansion
5. Progenitor Cell Therapy Secures Industry Accreditation
6. BIOCOM Institute Secures Non-Profit Designation and Funding
7. Cara Therapeutics Secures $12.3 Million in Series C Extension Financing
8. OMTEC 2008 Boasts Record Attendance and Secures Premier Position as Must-attend for Orthopaedic Companies
9. Genta Secures Up to $40 Million Convertible Financing Facility to Fund Key Programs
10. Novasys Medical Secures $49.5 Million in Series D Financing to Expand Commercialization of Its Renessa(R) Treatment for Incontinence in Women
11. Veran Medical Technologies Secures $4.75M in First Institutional Funding

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...OCKHOLM, November 20 Karolinska De...estment Fund (EIF) has entered into a,co-investmen...nd will be,managed by Karolinska Development and u...stage pharmaceutical and medical technology compan...co-investment fund. The agreement,represents EIF,s...
(Date:11/20/2009)... METTLER TOLEDO recently announced that Dr. Do...uo;The Role of Process Analytical Technology (PAT)...n December 1, 2009. , (PR...Process Analytical Technology (PAT) in Green Chemi... Process Analytical Technology (PAT) case studies ...
(Date:11/19/2009)...ov. 19 Omeros Corporatio...cial results for the third quarter ended September..., 2009, Omeros reported a net loss of $3.9 million... $7.4 million, or $2.54 per share, for the same pe...30, 2009, the Company reported a net loss of $15.5...
(Date:11/19/2009)...Nov. 19 NeoStem, Inc. (N... the following letter to its shareholders, discuss..., of China Biopharmaceuticals Holdings, Inc. (CHBP...in the People,s Republic of China. The merger give...e Pharmaceutical Co. Ltd., CHBP,s primary operatin...
Breaking Biology Technology:Karolinska Development and EIF Start Landmark Co-Investment Fund for Life Science Innovation 2Karolinska Development and EIF Start Landmark Co-Investment Fund for Life Science Innovation 3Process Analytical Technology (PAT) in Green Chemistry and Green Engineering 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 3
..., Mass., March 31 Tryton Medical, Inc., the,leadi... treatment of,bifurcation lesions announced today ... financing. Two new investors, PTV Sciences and Ri... Partners in the financing. Rick Anderson,from PTV...ted to the Tryton,Board of Directors., "Bifurcati...
...eneration Pyrosequencing(R) System; PyroMark(TM)Q2...or Low Throughput Epigenetic Studies, UPPSALA, Sw... Biotage AB today announced the launch of PyroMark...R) Systems. This new high-performance,platform inc... genetic and,epigenetic variation of genes, provid...
...Quarter 2008 Earnings Conference Call Thursday, Ma....S. EDT, FRAZER, Pa., March 31 Cephalon, Inc.,(...y earnings conference call,covering first quarter ...2008., May 1, 2008 Sched...tributed by PRNewswire 4:50 p.m. EDT To partic...
Other Biology Technology:Tryton Medical, Inc. Closes $14 Million Financing 2Tryton Medical, Inc. Closes $14 Million Financing 3Biotage Launches New 24 Well Pyrosequencing(R) System 2
(Date:11/22/2009)...xposed prenatally to tobacco smoke and during chil...HD, according to research done at Cincinnati Child...ates that up to 35 percent of ADHD cases in childr...y eliminating both of these environmental exposure...n , "Tobacco and lead exposure each have their ...
(Date:11/22/2009)...r 23, 2009 Agios Pharmaceuticals today announced ...t time, that the mutated IDH1 gene has a novel enz..., or oncogene. This breakthrough discovery shows t..., 2-hydroxyglutarate (2HG), which may contribute t...as, the most common type of brain cancers. This di...
(Date:11/20/2009)... all read studies about the health benefits of hav...molecular level, where amino acids known as cystei... than when paired up with other cysteines. , Now... with colleagues in Belgium, have discovered a new.... The research appears in the Nov. 20 issue of the...
Breaking Biology News(10 mins):Exposure to lead, tobacco smoke raises risk of ADHD 2Cancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer 2Cancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer 3Cancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer 4Saving the single cysteine: New antioxidant system found 2Maui Jim Teams With Unite for Sight in New Buy One Give One Program to Improve Eye Health Amongst the Worlds Most Needy 49888 1Maui Jim Teams With Unite for Sight in New Buy One Give One Program to Improve Eye Health Amongst the Worlds Most Needy 49888 2Maui Jim Teams With Unite for Sight in New Buy One Give One Program to Improve Eye Health Amongst the Worlds Most Needy 49888 3The Crohns 26 Colitis Foundation and Procter 26 Gamble Pharmaceuticals Announce 2009 Celebrating UC Success Contest Winners 49883 1The Crohns 26 Colitis Foundation and Procter 26 Gamble Pharmaceuticals Announce 2009 Celebrating UC Success Contest Winners 49883 2The Crohns 26 Colitis Foundation and Procter 26 Gamble Pharmaceuticals Announce 2009 Celebrating UC Success Contest Winners 49883 3The Crohns 26 Colitis Foundation and Procter 26 Gamble Pharmaceuticals Announce 2009 Celebrating UC Success Contest Winners 49883 4The Crohns 26 Colitis Foundation and Procter 26 Gamble Pharmaceuticals Announce 2009 Celebrating UC Success Contest Winners 49883 5Availability in Both Intravenous and Oral Formulation is a Leading Drug Attribute Surveyed Physicians Prefer for the Treatment of Urinary Tract Infect 49878 1Availability in Both Intravenous and Oral Formulation is a Leading Drug Attribute Surveyed Physicians Prefer for the Treatment of Urinary Tract Infect 49878 2Availability in Both Intravenous and Oral Formulation is a Leading Drug Attribute Surveyed Physicians Prefer for the Treatment of Urinary Tract Infect 49878 3
...tudy in 50 people in Japan suggests that eating tw...two months may confer some protection against a ra...d even stomach cancer. , Citing their new "demon...archer and an international team of scientists cau...id not cure infection by the bacterium Helicobact...
...ril 3 The General Services Administration (GSA) h...CH) as a provider of Personal Identity Verificatio...ation managed services, under Homeland Security Pr...fication, ABBTECH will offer services through thei...2 as an approved service provider. Services prov...
...chers from the Massachusetts General Hospital Cent... the first evidence of cell-to-cell communication ...ather than by known protein signaling agents such ... appear in an upcoming issue of the FASEB Journal... by complete surprise," says Rohit Jindal, PhD, a ...
Other Biology News:Gutsy germs succumb to baby broccoli 2Gutsy germs succumb to baby broccoli 3Gutsy germs succumb to baby broccoli 4ABBTECH Staffing Services Certified by GSA as an HSPD-12 Managed Service Provider 2Model tissue system reveals cellular communication via amino acids 2
Mouse Anti-GLP-1 Monoclonal Antibody, Unconjugated, Clone HYB 147-12 from Santa Cruz Biotechnology, Inc.
Baculovirus system service from Abgent
21-mer duplex design + syn.; 1 gene from B-Bridge International
EDTA, tetrasodium salt from GE Healthcare, formerly Amersham Biosciences
Biology Products: